IHC demonstrated expression of ESR1 by stromal cells but not epithelial cells (benign or malignant) in untreated samples, but 24% of degarelix-treated cancers stained positive for ESR1 in malignant epithelia compared with 8% of untreated samples (Fig. 2E). This evidence concerns the gene ESR1 and cancer.